Introduction: Assessing virological response of four-drugs antiretroviral regimen that include raltegravir (RAL) in naïve patients with high viral load ( 500,000 copies/mL) selected from a multicentre Italian database. Methods: Naïve patients with HIV RNA 500,000 copies/mL, who began standard antiretroviral regimens either based on nonnucleoside reverse transcriptase inhibitors (NNRTI) or boosted-PI (PI/r), or a standard regimen plus RAL between 2008 and 2013 were analyzed. Observation was censored at 12 months and the percentage of patients who achieved a viral load below the limit of detection (BLD) was calculated. Virological failure was defined as two consecutive viral loads 40 copies/mL. Results: Overall, 179 patients were included (13% with primary HIV infection (PHI), and 42.5% with AIDS diagnosis). Of them, 156 started standard three-drugs antiretroviral regimen (75.6% PI/r-based, 24.4% NNRTI-based. Among patients with PHI, 23 patients (12.8%), 6 (25%) started a four-drugs antiretroviral regimen containing both RAL and PI/r. Patients' characteristics were as follows: males 74%, median age 42 years (IQR 35Á51), sexually transmission 75.1%, median CD4 count 156 cells/mL (IQR 47Á 368) and median HIV-RNA 6.1 log10 copies/mL (IQR 5.8Á6.4). 91 of 179 patients (50.8%) reached BLD viral load during the twelve months of observation. Three patients (1.7%) who began regimens PI/r-based with three-drugs had virological rebound after reaching BLD viral load. By use of survival analysis, we show that those patients who added RAL to the standard regimen have reached the primary end point faster (mean 8.4 months (95% CI 7.2Á9.6) vs 11.4 (95% CI 11.0Á11.8) in PI group and 10.3
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